Navigation Links
Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
Date:10/29/2010

d collaboration agreement for development of the ActRIIB class of molecules.

SG&A % of % of product product Q3 2010 sales Q3 2009 sales $M $M SG&A (US GAAP) 392.4 49% 320.6 53% Intangible asset (31.2) (34.8) amortization Impairment of intangible (42.7) - assets Depreciation (16.1) (18.5) SG&A (Non GAAP) 302.4 38% 267.3 44%

SG&A increased in part due to increased sales and marketing costs incurred to support newly launched products (INTUNIV and VPRIV) and growth in new markets.

On a US GAAP basis, SG&A included an impairment charge of $42.7 million to write down the DAYTRANA intangible asset to its fair value less costs to sell following agreement to divest the product to Noven.

Reorganization costs

For the three months to September 30, 2010 Shire recorded reorganization costs of $9.7 million (2009: $2.0 million) relating to the transfer of manufacturing from its Owings Mills facility and the establishment of an international commercial hub in Switzerland.

Integration and acquisition costs

For the three months to September 30, 2010 Shire recorded integration and acquisition costs of $5.8 million (2009: $6.2 million), which in 2010 related to the acquisition of Movetis, and in 2009 to the integration of Jerini AG.

Interest expense

For the three months to September 30, 2010 the Company incurred interest expense of $8.3 million (2009: $9.4 million). Interest expense principally relates to the coupon and amortization of issue costs on Shire's $1,100 million 2.75% convertible bonds due 2014.

Taxation

The US GAAP effective rate of tax in Q3 2010 was 35% (2009: 34%), and the effective tax rate on Non GAAP income was 24% (2009: 33%).

The Non GAAP effective tax rate in both Q3 2010 and 2009 benefited from changes in estimate of the amount of certain tax liabilities following the submission of various tax returns. The Non GAAP eff
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
2. Reportlinker Adds Shire plc: PharmaVitae Profile
3. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
4. Shire plc - Statement re ProAmatine
5. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
6. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
7. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
8. Shire plc Appoints Two New Board Directors
9. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
10. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
11. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... Richardson, Texas (PRWEB) October 20, 2014 ... today announced that a team from Iowa State University ... * design contest. Using a Convey HC-2ex, the team’s ... than 14 times faster than the second place finisher. ... academic world embarked upon the month long challenge, using ...
(Date:10/20/2014)... , A major pan-European survey ... delivery of care has revealed changing trends in many ... the provision of healthcare services across the continent. The ... European Gastroenterology (UEG), have been announced today and led ... the burden of GI disorders across Europe ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... March 16 Micromet, Inc. (Nasdaq: MITI ), ... of cancer, inflammation and autoimmune diseases, today announced the publication ... meeting of AACR taking place from April 20-24, 2009, in ... , Lutterbuese, ...
... /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY ) ... of innovative therapeutic products for the treatment of cancer, ... a notice from the NASDAQ Hearings Panel that Oncothyreon ... of The NASDAQ Global Market. , The notice followed ...
... take two bricks and place them side by side a ... the bricks will be covered with snow and barely discernible. ... around the bricks. , What you will see, says Ivan ... smallest of scales on an integrated optical circuit, could hasten ...
Cached Biology Technology:Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 2Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 3Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 4Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 5Oncothyreon regains compliance with NASDAQ listing requirements 2New organic material may speed Internet access 2New organic material may speed Internet access 3New organic material may speed Internet access 4New organic material may speed Internet access 5
(Date:10/15/2014)... have linked increased resistance to bacterial pneumonia in female ... hormone estrogen. , Females are naturally more resistant to ... scientists has shown that increased resistance to bacterial pneumonia ... oxide synthase 3 (NOS3). They also show that this ... female sex hormone estrogen. , The team, lead by ...
(Date:10/15/2014)... be awarded the 44th Rosenstiel Award for Distinguished Work ... research exploring the mechanisms of genomic instability and its ... is the second alumnus to win the Rosenstiel Award; ... 2003. , Alt is the Charles A. Janeway Professor ... School and an investigator at the Howard Hughes Medical ...
(Date:10/14/2014)... thieves, prostate cancer tumors scavenge and hoard copper that ... avarice may be a fatal weakness. , Researchers ... prostate cancer cells by delivering a trove of copper ... cells brimming with the mineral, leaving non-cancer cells healthy. ... commercially available for other uses, could soon be tested ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Prostate cancer's penchant for copper may be a fatal flaw 2
... MANHATTAN, KAN. -- New findings about the causes of ... genetic. "We now know it,s also in the ... Professor of Diagnostic Medicine and Pathobiology at Kansas State ... ago, Richt said, it was thought that the cattle ...
... Neurons constituting the optic nerve wire up to the ... developing retina sprout processes, called axons, which extend toward visual ... U-turns when they take the wrong path. How they find ... Using the mouse visual system, a team of Salk ...
... CITY After years of working toward this goal, scientists ... isolate cancer stem cells in tumors so they can target ... A research team at the University of Oklahoma led ... a particular protein only appears in stem cells. Until now, ...
Cached Biology News:K-State professor's USDA research shows mad cow disease also caused by genetic mutation 2A second career for a growth factor receptor: keeping nerve axons on target 2A second career for a growth factor receptor: keeping nerve axons on target 3
MOUSE ANTI HUMAN CYTOKERATIN 1-8...
Immunogen: Tissue / cell preparation. (Murine EHS laminin preparation) Storage: -20 C, Avoid Freeze/Thaw Cycles...
p-Raf-1 (Ser 338/Tyr 341)-R...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Biology Products: